Compare ETON & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ETON | SPRY |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 872.7M | 788.5M |
| IPO Year | 2018 | 2020 |
| Metric | ETON | SPRY |
|---|---|---|
| Price | $42.85 | $6.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $39.33 | ★ $40.00 |
| AVG Volume (30 Days) | 524.8K | ★ 2.3M |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | $79,950,000.00 | ★ $84,278,000.00 |
| Revenue This Year | $40.90 | $87.40 |
| Revenue Next Year | $47.23 | $81.64 |
| P/E Ratio | $882.80 | ★ N/A |
| Revenue Growth | ★ 104.94 | N/A |
| 52 Week Low | $13.78 | $5.77 |
| 52 Week High | $44.91 | $18.63 |
| Indicator | ETON | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 69.26 | 28.16 |
| Support Level | $16.02 | N/A |
| Resistance Level | N/A | $8.61 |
| Average True Range (ATR) | 2.16 | 0.44 |
| MACD | 0.44 | -0.18 |
| Stochastic Oscillator | 84.11 | 13.90 |
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.